Researchers at the Translational Genomics Research Institute (TGen) today announced the discovery of previously unrecognized alterations in a gene called FGFR2 in a subset of endometrial cancers, the most common gynecologic cancer in the United States.
Doctor Mom?s admonition, “Don?t peel your apple,” is getting new scientific support from scientists in New York, who are reporting isolation of chemical compounds from apple peel that may be involved in the apple?s beneficial health effects.
The average person’s lifetime risk of developing colorectal cancer (CRC) is about seven percent and the role of diet in preventing this type of cancer remains under debate.
Research shows that the prevalence of obesity is rising, causing an increase in heart disease and diabetes, among other conditions, but evidence has not yet been established linking obesity to precancerous lesions in the colon called polyps.
Rates of colorectal cancer in elderly people are increasing, but there has been relatively little study of this disease in the “oldest” of the old or very elderly patients.
The incidence of colorectal cancer varies according to race, but little is known about how different races are affected by specific types of the disease.
Nearly three out of four ulcerative colitis sufferers (73 percent) responding to a new nationwide survey say not feeling well has become a normal part of life. Furthermore, they describe UC as disruptive when it comes to their relationship with a spouse (64 percent), their sexual relations (75 percent) and their emotional state (82 percent).
The American College of Obstetricians and Gynecologists (ACOG) announced a new education campaign aimed at reducing deaths from colorectal cancer among women. Colorectal cancer is the No. 2 cancer killer of adults in the US and the third leading cause of cancer death among women in the US, behind lung and breast cancers.
New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers. Reovirus, a non-pathogenic virus under development at Calgary, Alberta-based Oncolytics Biotech, has shown powerful anti-cancer activity against cultured tumor cells, in animal models, and in human clinical trials. Oncolytics’ proprietary reovirus formulation, Reolysin?, is active against numerous cancers, including intractable sarcomas and melanomas.
Higher Colon Cancer Risk in Uveal Melanoma Patients and Their Relatives Compared to General Population, will be presented by Frederick H. Davidorf, MD, during the Association for Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting in Fort Lauderdale, Fla. The presentation will take place on Wednesday, May 9 from 3:00 p.m. to 4:45 p.m. in Hall B/C of the Greater Fort Lauderdale/Broward County Convention Center.